experspadmin

Second-Generation Bruton Tyrosine Kinase Inhibitor Therapy in the Frontline Treatment Setting
Oncology

Second-Generation Bruton Tyrosine Kinase Inhibitor Therapy in the Frontline Treatment Setting

clinical topic updates
By Matthew S. Davids, MD, MMSc
Bruton Tyrosine Kinase Inhibitor Eligibility in Relapsed/Refractory Mantle Cell Lymphoma
Oncology

Bruton Tyrosine Kinase Inhibitor Eligibility in Relapsed/Refractory Mantle Cell Lymphoma

patient care perspectives
By John M. Pagel, MD, PhD
Migraine Triggers: Sleep, Stress, Food, and Other Factors
Neurology

Migraine Triggers: Sleep, Stress, Food, and Other Factors

patient care perspectives
By Deborah I. Friedman, MD, MPH, FAAN, FAHS
Risks Associated With Frequent Acute Migraines and Acute Treatment
Neurology

Risks Associated With Frequent Acute Migraines and Acute Treatment

patient care perspectives
By Paul G. Mathew, MD, DNBPAS, FAAN, FAHS
Moving Toward More Precisely Targeted Therapies for Plaque Psoriasis
Dermatology

Moving Toward More Precisely Targeted Therapies for Plaque Psoriasis

expert roundtables
By Alice B. Gottlieb, MD, PhD; Joel M. Gelfand, MD, MSCE; Steven R. Feldman, MD, PhD
Load More